These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

459 related items for PubMed ID: 31166755

  • 1. Comparison of Whole-Body DWI and 18F-FDG PET/CT for Detecting Intramedullary and Extramedullary Lesions in Multiple Myeloma.
    Chen J, Li C, Tian Y, Xiao Q, Deng M, Hu H, Wen B, He Y.
    AJR Am J Roentgenol; 2019 Sep; 213(3):514-523. PubMed ID: 31166755
    [Abstract] [Full Text] [Related]

  • 2. Prospective comparison of 18-FDG PET/CT and whole-body diffusion-weighted MRI in the assessment of multiple myeloma.
    Mesguich C, Hulin C, Latrabe V, Lascaux A, Bordenave L, Hindié E, Marit G.
    Ann Hematol; 2020 Dec; 99(12):2869-2880. PubMed ID: 32951093
    [Abstract] [Full Text] [Related]

  • 3. Diagnostic value of WB-DWI versus 18F-FDG PET/CT for the detection of multiple myeloma.
    Zhang B, Zhang L, Bian B, Lin F, Zhu Z, Wang J.
    Indian J Cancer; 2023 Dec; 60(3):303-309. PubMed ID: 37787189
    [Abstract] [Full Text] [Related]

  • 4. Diagnostic Value of Whole-Body DWI With Background Body Suppression Plus Calculation of Apparent Diffusion Coefficient at 3 T Versus 18F-FDG PET/CT for Detection of Bone Metastases.
    Sun W, Li M, Gu Y, Sun Z, Qiu Z, Zhou Y.
    AJR Am J Roentgenol; 2020 Feb; 214(2):446-454. PubMed ID: 31799866
    [Abstract] [Full Text] [Related]

  • 5. Diagnostic performance of 18F-FDG PET/CT and whole-body MRI before and early after treatment of multiple myeloma: a prospective comparative study.
    Basha MAA, Hamed MAG, Refaat R, AlAzzazy MZ, Bessar MA, Mohamed EM, Ahmed AF, Tantawy HF, Altaher KM, Obaya AA, Afifi AHM.
    Jpn J Radiol; 2018 Jun; 36(6):382-393. PubMed ID: 29671193
    [Abstract] [Full Text] [Related]

  • 6. 18F-FDG PET/CT and whole-body MRI diagnostic performance in M staging for non-small cell lung cancer: a systematic review and meta-analysis.
    Machado Medeiros T, Altmayer S, Watte G, Zanon M, Basso Dias A, Henz Concatto N, Hoefel Paes J, Mattiello R, de Souza Santos F, Mohammed TL, Verma N, Hochhegger B.
    Eur Radiol; 2020 Jul; 30(7):3641-3649. PubMed ID: 32125513
    [Abstract] [Full Text] [Related]

  • 7. Whole-body low-dose CT recognizes two distinct patterns of lytic lesions in multiple myeloma patients with different disease metabolism at PET/MRI.
    Zambello R, Crimì F, Lico A, Barilà G, Branca A, Guolo A, Varin C, Vezzaro R, Checuz L, Scapin V, Berno T, Pizzi M, Ponzoni A, De Biasi E, Vio S, Semenzato G, Zucchetta P, Lacognata C.
    Ann Hematol; 2019 Mar; 98(3):679-689. PubMed ID: 30539276
    [Abstract] [Full Text] [Related]

  • 8. Whole-body MRI with diffusion-weighted imaging: a valuable alternative to contrast-enhanced CT for initial staging of aggressive lymphoma.
    Balbo-Mussetto A, Cirillo S, Bruna R, Gueli A, Saviolo C, Petracchini M, Fornari A, Lario CV, Gottardi D, De Crescenzo A, Tarella C.
    Clin Radiol; 2016 Mar; 71(3):271-9. PubMed ID: 26749081
    [Abstract] [Full Text] [Related]

  • 9. Correlation of simultaneously acquired diffusion-weighted imaging and 2-deoxy-[18F] fluoro-2-D-glucose positron emission tomography of pulmonary lesions in a dedicated whole-body magnetic resonance/positron emission tomography system.
    Schmidt H, Brendle C, Schraml C, Martirosian P, Bezrukov I, Hetzel J, Müller M, Sauter A, Claussen CD, Pfannenberg C, Schwenzer NF.
    Invest Radiol; 2013 May; 48(5):247-55. PubMed ID: 23519008
    [Abstract] [Full Text] [Related]

  • 10. Whole-body MRI, FDG-PET/CT, and bone marrow biopsy, for the assessment of bone marrow involvement in patients with newly diagnosed lymphoma.
    Albano D, Patti C, Lagalla R, Midiri M, Galia M.
    J Magn Reson Imaging; 2017 Apr; 45(4):1082-1089. PubMed ID: 27603267
    [Abstract] [Full Text] [Related]

  • 11. Diagnostic performance of 18F-FDG PET/CT and whole-body diffusion-weighted imaging with background body suppression (DWIBS) in detection of lymph node and bone metastases from pediatric neuroblastoma.
    Ishiguchi H, Ito S, Kato K, Sakurai Y, Kawai H, Fujita N, Abe S, Narita A, Nishio N, Muramatsu H, Takahashi Y, Naganawa S.
    Ann Nucl Med; 2018 Jun; 32(5):348-362. PubMed ID: 29667143
    [Abstract] [Full Text] [Related]

  • 12. Whole-body MRI with diffusion-weighted sequence for staging of patients with suspected ovarian cancer: a clinical feasibility study in comparison to CT and FDG-PET/CT.
    Michielsen K, Vergote I, Op de Beeck K, Amant F, Leunen K, Moerman P, Deroose C, Souverijns G, Dymarkowski S, De Keyzer F, Vandecaveye V.
    Eur Radiol; 2014 Apr; 24(4):889-901. PubMed ID: 24322510
    [Abstract] [Full Text] [Related]

  • 13. Diagnostic performance of computed tomography and diffusion-weighted imaging as first-line imaging modality according to the International Myeloma Working Group (IMWG) imaging algorithm for monoclonal plasma cell disorders.
    Yoon MA, Chee CG, Chung HW, Lee DH, Kim KW.
    Acta Radiol; 2022 May; 63(5):672-683. PubMed ID: 33853375
    [Abstract] [Full Text] [Related]

  • 14. Detection of bone metastases in non-small cell lung cancer patients: comparison of whole-body diffusion-weighted imaging (DWI), whole-body MR imaging without and with DWI, whole-body FDG-PET/CT, and bone scintigraphy.
    Takenaka D, Ohno Y, Matsumoto K, Aoyama N, Onishi Y, Koyama H, Nogami M, Yoshikawa T, Matsumoto S, Sugimura K.
    J Magn Reson Imaging; 2009 Aug; 30(2):298-308. PubMed ID: 19629984
    [Abstract] [Full Text] [Related]

  • 15. Optimization of whole-body 2-[18F]FDG-PET/MRI imaging protocol for the initial staging of patients with myeloma.
    Burns R, Mulé S, Blanc-Durand P, Tofighi M, Belhadj K, Zerbib P, Le Bras F, Baranes L, Haioun C, Itti E, Luciani A.
    Eur Radiol; 2022 May; 32(5):3085-3096. PubMed ID: 34842956
    [Abstract] [Full Text] [Related]

  • 16. Whole-body diffusion-weighted imaging vs. FDG-PET for the detection of non-small-cell lung cancer. How do they measure up?
    Chen W, Jian W, Li HT, Li C, Zhang YK, Xie B, Zhou DQ, Dai YM, Lin Y, Lu M, Huang XQ, Xu CX, Chen L.
    Magn Reson Imaging; 2010 Jun; 28(5):613-20. PubMed ID: 20418042
    [Abstract] [Full Text] [Related]

  • 17. Staging performance of whole-body DWI, PET/CT and PET/MRI in invasive ductal carcinoma of the breast.
    Catalano OA, Daye D, Signore A, Iannace C, Vangel M, Luongo A, Catalano M, Filomena M, Mansi L, Soricelli A, Salvatore M, Fuin N, Catana C, Mahmood U, Rosen BR.
    Int J Oncol; 2017 Jul; 51(1):281-288. PubMed ID: 28535000
    [Abstract] [Full Text] [Related]

  • 18. Usefulness of both PET/CT with F18-FDG and whole-body diffusion-weighted imaging in cancer screening: a preliminary report.
    Sasamori H, Uno K, Wu J.
    Ann Nucl Med; 2019 Feb; 33(2):78-85. PubMed ID: 30298377
    [Abstract] [Full Text] [Related]

  • 19. Agreement Between 18F-FDG PET/CT and Whole-Body Magnetic Resonance Compared With Skeletal Survey for Initial Staging and Response at End-of-Treatment Evaluation of Patients With Multiple Myeloma.
    Gómez León N, Aguado Bueno B, Herreros Pérez M, León Ramírez LF, Alegre A, Colletti PM, Rubello D, Carreras JL, Delgado Bolton RC.
    Clin Nucl Med; 2021 Apr 01; 46(4):310-322. PubMed ID: 33534256
    [Abstract] [Full Text] [Related]

  • 20. A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma.
    Zamagni E, Nanni C, Patriarca F, Englaro E, Castellucci P, Geatti O, Tosi P, Tacchetti P, Cangini D, Perrone G, Ceccolini M, Brioli A, Buttignol S, Fanin R, Salizzoni E, Baccarani M, Fanti S, Cavo M.
    Haematologica; 2007 Jan 01; 92(1):50-5. PubMed ID: 17229635
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.